Addressing Unmet Needs In Melanoma

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Addressing Unmet Needs In Melanoma

Playback speed

10 seconds

ASCO 2022 Phase II SECOMBIT Study on Optimal Treatment Sequencing in BRAF-Mutated Melanoma: A Subgroup Analysis With a Longer Follow-Up

By ASCO 2022 Conference Coverage FEATURING Paolo A. Ascierto

110 views

June 16, 2022

Comments 0

ASCO 2022 Long-Term Survival in Advanced Melanoma for Pts Treated Wi…

ASCO 2022 Conference Coverage

P. Rutkowski

132 views

ASCO 2022 on RELATIVITY-047 Trial: Nivolumab + Relatlimab vs. Nivo i…

ASCO 2022 Conference Coverage

P. Rutkowski

1.1K views

ASCO 2022: Real-World Evaluation of the Association Between Baseline…

ASCO 2022 Conference Coverage

Z. Eroglu

130 views

ASCO 2022 on ImmunoCobiVem Study Interim Analysis: The Efficacy & Sa…

ASCO 2022 Conference Coverage

E. Livingstone

124 views

ASCO 2022 on the Role of Metastasectomy in Advanced BRAF+ Melanoma D…

ASCO 2022 Conference Coverage

K. Orlova

300 views

ASCO 2022 Meta-Analysis of Randomized Phase II-III Trials Evaluating…

ASCO 2022 Conference Coverage

P. Francesco Ferrucci

110 views

Lecture Summary - ASCO 2022 Meta-Analysis of Randomized Phase II-III…

ASCO 2022 Conference Coverage

P. Francesco Ferrucci

11 views

ASCO 2022 Melanoma Updates

Total Health

G. Doolittle

263 views

Penn Medicine on the Treatment Updates in Melanoma: Head-Spinning Pr…

Penn Medicine Abramson Cancer Center

L. Schuchter

251 views

ASCO 2022 Nivo + Rela vs. Nivo in Previously Untreated Metastatic/Un…

ASCO 2022 Conference Coverage

E. Lipson

336 views

ASCO 2022 on Anti-PD-1 Antibody: Plus One or Plus Two

ASCO 2022 Conference Coverage

A. Daud

270 views

Lecture Summary - ASCO 2022 on Anti-PD-1 Antibody: Plus One or Plus …

ASCO 2022 Conference Coverage

A. Daud

15 views

ASCO 2022 Updates on DREAMseq (Doublet, Randomized Evaluation in Adv…

ASCO 2022 Conference Coverage

M. Atkins

215 views